| 摘要: |
| 【摘要】 目的：探究超声双重造影和超声内镜在进展期胃癌（AGC）新辅助治疗后再分期的一致性。方法：回顾性分析2018年1月至2020年1月本院治疗的63例AGC患者病历资料，在进行新辅助治疗后，均接受超声双重踪影和超声内镜检查，分析这两种检查方式对新辅助治疗后患者T分期、病灶大小及周围组织侵犯情况。结果：63例AGC患者中，超声双重造影诊断显示，T2期12例，T3期34例，T4期17例；超声内镜诊断显示，T2期11例，T3期32例，T4期20例。超声双重造影与超声内镜对新辅助治疗后T分期诊断的一致率为84.13%，且一致性较强（Kappa=0.738）。超声双重造影与超声内镜对新辅助治疗后病灶左右径、纵轴径、前后径的评估价值比较，差异均无统计学意义（P＞0.05）。超声双重造影与超声内镜对新辅助治疗后是否侵犯横结肠及其系膜的诊断一致率为79.37%，且一致性中等（Kappa=0.471）。超声双重造影与超声内镜对新辅助治疗后肝、脾侵犯诊断的一致率为71.43%，且一致性中等（Kappa=0.581）。超声双重造影与超声内镜对新辅助治疗后十二指肠、胰腺侵犯诊断的一致率为73.02%，且一致性中等（Kappa=0.613）。结论：超声双重造影和超声内镜在AGC新辅助治疗后T分期、病灶大小一致性较高，但对组织侵犯情况评估的一致性中等。 |
| 关键词: 超声双重造影 超声内镜 进展期胃癌 再分期 |
| DOI： |
| 投稿时间：2021-08-16修订日期：2021-09-02 |
| 基金项目:lncRNA对萎缩性胃炎患者的胃癌风险预警及应用 |
|
| Concordance of ultrasound dual imaging and ultrasound endoscopy in re-staging of progressive gastric cancer after neoadjuvant therap |
| zhouli,Denglei,Liushuni,Xiaoxiao,Wanxiaoqiang,Zhengzidan |
| () |
| Abstract: |
| 【Abstract】 Objective: To investigate the concordance between ultrasound dual imaging and ultrasound endoscopy in the re-staging of progressive gastric cancer (AGC) after neoadjuvant therapy. Methods: Retrospective analysis of medical records of 63 patients with AGC treated in our hospital from January 2018 to January 2020, who underwent dual ultrasound tracing and ultrasound endoscopy after neoadjuvant therapy, and analysis of the T-stage, lesion size and surrounding tissue invasion of patients after neoadjuvant therapy by these two examination modalities. Results: Among 63 patients with AGC, dual ultrasonography diagnosis showed 12 cases of T2 stage, 34 cases of T3 stage and 17 cases of T4 stage, while ultrasound endoscopy diagnosis showed 11 cases of T2 stage, 32 cases of T3 stage and 20 cases of T4 stage. The agreement rate between dual ultrasonography and ultrasound endoscopy for the diagnosis of T-stage after neoadjuvant therapy was 84.13% with strong agreement (Kappa=0.738). There was no statistically significant difference in the value of double ultrasonography versus ultrasound endoscopy for the assessment of right and left, longitudinal and anterior and posterior diameters of lesions after neoadjuvant treatment (P > 0.05). The diagnostic agreement between dual ultrasonography and ultrasound endoscopy on whether the transverse colon and its mesentery were invaded after neoadjuvant treatment was 79.37% and moderate (Kappa=0.471). The agreement rate between dual ultrasonography and ultrasound endoscopy for the diagnosis of liver and spleen invasion after neoadjuvant therapy was 71.43% with moderate agreement (Kappa=0.581). The concordance rate between dual ultrasonography and ultrasound endoscopy for the diagnosis of duodenal and pancreatic invasion after neoadjuvant therapy was 73.02% with moderate concordance (Kappa=0.613). Conclusion:Ultrasound dual contrast and endoscopy after AGC neoadjuvant treatment have a high consistency in T staging and lesion size, but the consistency in the assessment of tissue invasion is moderate. |
| Key words: Ultrasound dual imaging ultrasound endoscopy progressive gastric cancer restaging |
